Norovirus VLP intranasal vaccine: Phase I/II data

Data from the per protocol (PP) population (n=77) of a double-blind, U.S. Phase I/II trial in 84 healthy volunteers ages 18-50 who were challenged with live norovirus showed that LigoCyte's intranasal...